Relationship of Dose to the Reactogenicity and Immunogenicity of Meningococcal Polysaccharide Vaccines in Adults

Jm, Griffiss; Bl, Brandt; Dd, Broud; Pl, Altieri; Sl, Berman

doi:10.1093/milmed/150.10.529

Cited by 6 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The vaccine lot contained no proteins or LOS that could be detected by SDS-PAGE analysis. Each vaccinate responded appropriately to the group C polysaccharide (11).…”

Section: Methodsmentioning

confidence: 99%

Measurement of the human immune response to meningococcal lipooligosaccharide antigens by using serum to inhibit monoclonal antibody binding to purified lipooligosaccharide

Estabrook¹,

Mandrell²,

Apicella³

et al. 1990

Infect Immun

View full text Add to dashboard Cite

We developed a human inhibition monoclonal enzyme-linked immunosorbent assay (HIMELISA) to investigate the human immune response to the lipooligosaccharides (LOS) of Neisseria meningitidis. Monoclonal antibodies (MAb) were used to define seven epitopes on four LOS molecules of a meningococcal strain (126E) previously shown to express immunogenic LOS epitopes. The assay could distinguish epitope-specific antibody within whole sera. Neither the specificity nor the amount of the antibody measured by HIMELISA in sera of vaccinates changed during the immune response to meningococcal capsular polysaccharides, a chemically unrelated antigen. By using the HIMELISA, it was determined that sera from adults convalescing from meningococcal disease strongly inhibited MAb binding to two of the seven defined epitopes. The 3.6-kilodalton LOS of strain 126E expressed both of these epitopes. In addition, one of the inhibited epitopes was also expressed on the 4.0-kilodalton LOS of strain 126E. The convalescent-phase sera inhibited MAb binding to these two epitopes when they were expressed on LOS of diverse meningococcal strains. An acute-phase serum blocked MAb to the two epitopes to a lesser degree than did a convalescent-phase serum from the same patient. Immunoblotting the sodium dodecyl sulfate-polyacrylamide gel electrophoresisseparated LOS with convalescent-phase sera confirmed the specificity of the human anti-LOS antibody identified by HIMELISA.

show abstract

“…The vaccine lot contained no proteins or LOS that could be detected by SDS-PAGE analysis. Each vaccinate responded appropriately to the group C polysaccharide (11).…”

Section: Methodsmentioning

confidence: 99%

Measurement of the human immune response to meningococcal lipooligosaccharide antigens by using serum to inhibit monoclonal antibody binding to purified lipooligosaccharide

Estabrook¹,

Mandrell²,

Apicella³

et al. 1990

Infect Immun

View full text Add to dashboard Cite

show abstract

“…Diversas vacinas têm sido produzidas contra os meningococos A, B e C, os mais comuns nas endemias e epidemias e mesmo contra os sorogrupos Y e W135 que podem ocasionar surtos esporádicos em academias militares e educandários. Uma vacina de polissacáride 29E foi experimentada por Griffiss e col. 42 com resultados imunogênicos satisfatórios em adultos. As vacinas monovalentes A e C, a bivalente AC e a tetravalente ACYW135 vêm sendo empregadas com freqüência nos Estados Unidos, Europa e Amé-rica do Sul.…”

Section: Introductionunclassified

Comportamento imunológico das vacinas anti-meningocócicas

Requejo

1997

Rev. Saúde Pública

View full text Add to dashboard Cite

A doença meningocócica continua sendo um grande problema de saúde pública em todos os continentes, e as vacinas anti-meningocócicas têm sido indicadas na prevenção e controle de epidemias. As vacinas polissacarídicas A e C são relativamente eficazes, com comportamentos imunológicos distintos frente às faixas etárias; no entanto, para o sorogrupo B, embora existam numerosos estudos internacionais até agora já desenvolvidos, ainda não se tem uma vacina altamente segura e eficaz de ampla aceitação. O polissacáride capsular do meningococo B não é imunogênico devido ao seu mimetismo com componentes celulares do hospedeiro. Tentativas de se introduzir carreadores protéicos vêm sendo feitas para se obter uma vacina que seja imunogênica em todas as faixas etárias e de preferência protetora contra todos os meningococos. Foi feita revisão da literatura com o objetivo de estudar o comportamento imunológico de todas as vacinas, até então desenvolvidas, e mostrar os esforços que estão sendo empreendidos no sentido de se buscar um produto seguro e eficaz para o controle da doença meningocócica

show abstract

Tetravalent meningococcal polysaccharide vaccine. Relationship of dose to immunogenicity and reactogenicity in young adults

Brandt

Griffiss

Broud

et al. 1988

Gonococci and Meningococci

View full text Add to dashboard Cite

Relationship of Dose to the Reactogenicity and Immunogenicity of Meningococcal Polysaccharide Vaccines in Adults

Cited by 6 publications

References 0 publications

Measurement of the human immune response to meningococcal lipooligosaccharide antigens by using serum to inhibit monoclonal antibody binding to purified lipooligosaccharide

Measurement of the human immune response to meningococcal lipooligosaccharide antigens by using serum to inhibit monoclonal antibody binding to purified lipooligosaccharide

Comportamento imunológico das vacinas anti-meningocócicas

Tetravalent meningococcal polysaccharide vaccine. Relationship of dose to immunogenicity and reactogenicity in young adults

Contact Info

Product

Resources

About